Finch throws in the towel on microbiome journey, lets go of 77 employees

Finch Therapeutics’ attempt to make crapsules that help prevent the recurrence of a bacterial infection is nearing the end of the road.

For the third time in nine months, the Boston-area biotech will lay off staffers, this time 95%, which equates to 77 employees.

As is becoming more and more familiar in biotech these days, Finch flashed red lights early Tuesday, saying it will scrap a Phase III trial testing its donor stool-in-a-capsule for the prevention of recurring infection from the bacteria Clostridioides difficile, or C. diff.

Instead, the biotech will put all efforts into “realizing the value of its intellectual property estate and other assets,” according to a press release. The penny stock $FNCH has lost almost all its value since going public in the spring of…
Click here to view original post